Seaport Therapeutics (NASDAQ:SPTX) Issues Earnings Results, Beats Estimates By $0.30 EPS

Seaport Therapeutics (NASDAQ:SPTXGet Free Report) released its quarterly earnings results on Monday. The company reported ($10.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($10.64) by $0.30, Zacks reports.

Seaport Therapeutics Stock Performance

Shares of SPTX stock opened at $16.44 on Monday. Seaport Therapeutics has a twelve month low of $14.85 and a twelve month high of $23.00.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Seaport Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Leerink Partners assumed coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They set an “overweight” rating and a $42.00 price target on the stock. BNP Paribas Exane downgraded Seaport Therapeutics to a “market perform” rating in a research note on Tuesday, May 26th. Finally, Zacks Research upgraded Seaport Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $35.50.

Get Our Latest Research Report on SPTX

Insider Buying and Selling at Seaport Therapeutics

In related news, major shareholder Arch Venture Partners Xii, Llc bought 1,100,000 shares of the stock in a transaction on Monday, May 4th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the purchase, the insider owned 6,294,951 shares of the company’s stock, valued at $113,309,118. This trade represents a 21.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

See Also

Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.